34945.jpg
ProQR Announces Results for the First Quarter of 2018
May 09, 2018 07:00 ET | ProQR Therapeutics N.V.
Key updates Eight out of twelve patients have been enrolled in a Phase 1/2 clinical trial of QR-110 in adults and children with LCA 10. Interim data are expected in the second half of 2018, with...
34945.jpg
ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB
April 30, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
logo_ProQR-150x150.png
ProQR to Present at Two Upcoming Conferences
April 03, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, April 03, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
logo_ProQR-150x150.png
ProQR to Present at Upcoming Investor Conference
March 05, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, March 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
logo_ProQR-150x150.png
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
February 12, 2018 07:00 ET | ProQR Therapeutics N.V.; Foundation Fighting Blindness
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting...
logo_ProQR-150x150.png
ProQR to Present at Upcoming Scientific Meeting and Investor Conference
February 06, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...
logo_ProQR-150x150.png
ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
January 08, 2018 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V....
logo_ProQR-150x150.png
ProQR Announces Extraordinary General Meeting of Shareholders
December 27, 2017 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), today announced that an Extraordinary General Meeting of Shareholders will be held on Monday,...
logo_ProQR-150x150.png
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
November 29, 2017 07:00 ET | ProQR Therapeutics N.V.
Key Updates ProQR’s drug candidate, QR-313 for dystrophic epidermolysis bullosa (DEB) receives orphan drug designation in the EU from the EMA.QR-313 also received U.S. ODD from the FDA in September...
logo_ProQR-150x150.png
ProQR to Present at the Annual Piper Jaffray Healthcare Conference
November 21, 2017 07:00 ET | ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Nov. 21, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.(Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the...